Langabeer, S. et al. 2023. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia. Experimental Oncology. 41, 1 (Jun. 2023), 82–83. DOI:https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12685.